Published in Nat Rev Drug Discov on April 01, 2002
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
Direct conversion of C. elegans germ cells into specific neuron types. Science (2010) 3.31
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer (2007) 3.28
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A (2004) 3.27
Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation (2006) 2.70
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest (2003) 2.26
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) (2007) 1.98
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett (2008) 1.98
An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A (2002) 1.91
Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology (2009) 1.81
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.80
WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A (2003) 1.78
Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 1.77
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol (2007) 1.77
Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer (2006) 1.73
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A (2006) 1.71
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev (2006) 1.70
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab (2012) 1.67
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc (2008) 1.64
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol (2013) 1.64
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog (2014) 1.59
Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med (2005) 1.56
Epigenetics: A New Bridge between Nutrition and Health. Adv Nutr (2010) 1.51
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem (2009) 1.48
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet (2009) 1.46
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Histone deacetylase–mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity. Kidney Int (2016) 1.38
Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther (2005) 1.37
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis (2007) 1.35
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res (2008) 1.34
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol (2010) 1.30
(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J Med Chem (2010) 1.30
HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem (2008) 1.29
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia (2009) 1.27
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc Natl Acad Sci U S A (2007) 1.26
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A (2007) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968. Appl Environ Microbiol (2007) 1.25
Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett (2009) 1.23
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One (2012) 1.22
Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med (2011) 1.21
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells (2009) 1.20
Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer (2005) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res (2008) 1.18
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol (2010) 1.17
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A (2011) 1.17
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res (2013) 1.12
Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Sci Rep (2012) 1.11
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 1.11
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development (2010) 1.10
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol (2007) 1.10
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther (2009) 1.09
Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol (2011) 1.08
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer (2009) 1.07
The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis (2005) 1.07
Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm (2011) 1.06
Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem (2009) 1.06
Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol (2004) 1.05
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis (2011) 1.05
Synthesis and characterization of SIRT6 protein coated magnetic beads: identification of a novel inhibitor of SIRT6 deacetylase from medicinal plant extracts. Anal Chem (2011) 1.04
Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer (2006) 1.04
Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer (2008) 1.04
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol (2007) 1.04
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J Med Chem (2010) 1.03
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Mod Rheumatol (2009) 1.03
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal (2012) 1.01
Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. Chromosoma (2007) 0.99
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One (2014) 0.99
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med (2013) 0.98